Last $2.49 USD
Change Today -0.0199 / -0.79%
Volume 40.3K
PSTI On Other Exchanges
Tel Aviv
As of 10:51 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

pluristem therapeutics inc (PSTI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/14 - $4.63
52 Week Low
12/5/14 - $2.42
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

pluristem therapeutics inc (PSTI) Related Businessweek News

No Related Businessweek News Found

pluristem therapeutics inc (PSTI) Details

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women’s health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

160 Employees
Last Reported Date: 09/11/14
Founded in 2001

pluristem therapeutics inc (PSTI) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $503.7K
President and Chief Operating Officer
Total Annual Compensation: $270.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $129.9K
Compensation as of Fiscal Year 2014.

pluristem therapeutics inc (PSTI) Key Developments

Pluristem and Hadassah Medical Center Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Pluristem Therapeutics Inc. announced that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center's Department of Bone Marrow Transplantation and Cancer Immunotherapy, headed by Professor Reuven Or, will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. PLX-RAD cells are Pluristem's second cell therapy product candidate.

Pluristem Therapeutics, Inc. Presents at Israel's 7th Annual Corporate Finance Conference, Nov-11-2014

Pluristem Therapeutics, Inc. Presents at Israel's 7th Annual Corporate Finance Conference, Nov-11-2014 . Venue: Leonardo City Tower, RamatGan, Israel. Speakers: Yaky Yanay, President and Chief Operating Officer.

Pluristem Therapeutics Announces Umbilical Cord Blood Transplantation Study by Case Western

Pluristem Therapeutics Inc. has announced that researchers at Case Western Reserve University will conduct a preclinical study of the company's PLacental eXpanded, or PLX,-RAD cells. The study will reportedly evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation. The study at Case Western Reserve will research the feasibility of using PLX-RAD cells to help the cord blood to engraft more effectively, resulting in higher rates of successful transplantation and treatment. PLX-RAD cells are also being studied by the US National Institutes of Health (NIH) for the treatment of acute radiation syndrome (ARS), which involves bone marrow failure after exposure to high levels of radiation, as can happen after a nuclear catastrophe. The primary objective of the study at Case Western Reserve is to determine the benefits of administering PLX-RAD cells at the time of transplantation of human hematopoietic CD34+ cells collected from umbilical cord blood. Scientists will compare the success rates of transplant engraftment in the control arm versus those treated with PLX-RAD cells. The secondary objective is to determine if there are any histologic changes in the liver, lung, spleen and intestine in the control versus treated groups. The preclinical study will be conducted in an immunodeficient mouse model that has undergone non-lethal radiation to destroy its own bone marrow cells. There will be three arms in the study: IV (intravenous) injection of human Hematopoietic Cells (hHC) alone for the control; IV injection of hHC plus IV injection of 1 million PLX-RAD cells; and IV injection of hHC plus intramuscular (IM) injection of 1 million PLX RAD cells. At 8 weeks bone marrow of the mice will be analyzed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSTI:US $2.49 USD -0.0199

PSTI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.28 USD -0.01
Cardica Inc $0.62 USD -0.0252
NeoStem Inc $3.26 USD +0.01
Ocata Therapeutics Inc $6.59 USD -0.10
StemCells Inc $0.98 USD -0.0117
View Industry Companies

Industry Analysis


Industry Average

Valuation PSTI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 457.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 342.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PLURISTEM THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at